Dr. Alavi founded 712 North in 2016 based on his unique insights into the mitochondrial biology in health and disease. Dr. Alavi is an inventor and has co-authored more than 20 peer-reviewed scientific publications. He holds a Ph.D. with summa cum laude from the Eberhard-Karls University Tübingen in Germany and completed postdoctoral training at UCSF, where his research centered on stress response pathways in the eye. He founded two early stage biotech companies and is a member of the Scientific Advisory Board of the Autosomal Dominant Optic Atrophy Association, ADOAA.
Emerging Therapeutics Showcase:
712 North Inc.
712 North is a pre-clinical stage pharmaceutical company based in California. We develop personalized mitochondrial medicines for a range of age-related diseases such as Alzheimer's, cancer, glaucoma, and cardiovascular disease.
Advancing Personalized Mitochondrial Medicines
Epidemiological data revealed an inverse correlation of Alzheimer’s disease and cancer, which suggests a carefully maintained balance tips over time. Mitochondria are at the intersection of both diseases and can explain the inverse correlation of both diseases. This implies each of us requires an individual adaption of this mitochondrial balance as we age. A pledge for personalized mitochondrial medicines.
The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.